Source comparison
CJC-1295 Before and After: Comparison of Protocol Variables
CJC-1295 DAC 60 mcg/kg (5–6 mg for 90 kg subject), once weekly 2–3 weeks for IGF-1 elevation; 8–12 weeks for body composition changes Using non-DAC dosing with weekly frequency. Results in subtherapeutic levels DAC formulation allows weekly dosing; non-DAC req
This comparison does not assign a generated winner or score.
- CJC-1295 DAC
- 60 mcg/kg (5–6 mg for 90 kg subject), once weekly
- 2–3 weeks for IGF-1 elevation; 8–12 weeks for body composition changes
- Using non-DAC dosing with weekly frequency. Results in subtherapeutic levels
- DAC formulation allows weekly dosing; non-DAC requires daily administration
- Non-DAC CJC-1295 (Mod GRF 1-29)
- 100–200 mcg per injection, daily
- 2–3 weeks for IGF-1 elevation with consistent daily dosing
- Skipping doses or irregular timing. Disrupts plasma stability
- Requires strict adherence; missed doses eliminate cumulative effect
- Reconstitution Method
- 2 mL bacteriostatic water per 5 mg vial (2.5 mg/mL concentration)
- N/A. Affects potency, not timeline
- Vigorous shaking during mixing. Denatures peptide structure
- Gentle swirling only; allow 5–10 minutes for complete dissolution
- Storage Post-Reconstitution
- 2–8°C refrigeration, use within 28 days
- N/A. Affects potency retention
- Storing at room temperature or freezing reconstituted solution
- Any excursion above 8°C causes irreversible protein degradation
- Injection Timing
- Pre-bed administration to align with natural GH secretion peak
- Timing influences amplitude but not timeline
- Random injection times without consistency. Reduces protocol efficacy
- Consistent timing optimizes circadian GH pulse alignment